L-carnitine supplementation in childhood epilepsy: current perspectives |
| |
Authors: | DC De Vivo TP Bohan DL Coulter FE Dreifuss RS Greenwood DR Nordli WD Shields CE Stafstrom I Tein |
| |
Affiliation: | Neurological Institute, Columbia-Presbyterian Medical Center, New York, New York 10032, USA. |
| |
Abstract: | In November 1996, a panel of pediatric neurologists met to update the consensus statement issued in 1989 by a panel of neurologists and metabolic experts on L-carnitine supplementation in childhood epilepsy. The panelists agreed that intravenous L-carnitine supplementation is clearly indicated for valproate (VPA)-induced hepatotoxicity, overdose, and other acute metabolic crises associated with carnitine deficiency. Oral supplementation is clearly indicated for the primary plasmalemmal carnitine transporter defect. The panelists concurred that oral L-carnitine supplementation is strongly suggested for the following groups as well: patients with certain secondary carnitine-deficiency syndromes, symptomatic VPA-associated hyperammonemia, multiple risk factors for VPA hepatotoxicity, or renal-associated syndromes; infants and young children taking VPA; patients with epilepsy using the ketogenic diet who have hypocarnitinemia; patients receiving dialysis; and premature infants who are receiving total parenteral nutrition. The panel recommended an oral L-carnitine dosage of 100 mg/kg/day, up to a maximum of 2 g/day. Intravenous supplementation for medical emergency situations usually exceeds this recommended dosage. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|